title: Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase.
abstract: The elevated exogenous-methionine dependency of tumors for growth has been observed in all major cancer cell types. We have previously cloned a methioninase (rMETase) from Pseudomonas putida to deplete methionine. Growth inhibition followed by apoptotic cell death was induced by treatment of tumor cells with rMETase in vitro. A single i.p. injection of 300 units of rMETase can lower the serum methionine level in the mice from 70 microM to less than 1 microM within 2 h and maintain this depleted level for 8 h. Repeated dosing of rMETase of tumor-bearing mice could be administered without acute immune-hypersensitivity. rMETase treatment demonstrated growth inhibitory activity against human tumors in nude mice, including those which were multiple drug-resistant. No body weight loss or hematotoxicity, except a slight anemia, was found throughout the therapy. The combined treatment of the Lewis lung carcinoma with a fixed rMETase dose and increasing doses of 5-fluorouracil (5-FU) resulted in a dose-dependent enhanced antitumor efficacy for survival as well as tumor growth inhibition. Thus, methionine depletion by rMETase potentiates the antitumor efficacy of 5-FU. The data presented in this report thus indicate that rMETase is active alone, is synergistic in combination with 5-FU, and has negligible toxicity suggesting a novel clinical approach for effective cancer therapy.
authors.affiliation: Discovery Research Laboratories II, Shionogi and Co., Ltd., Osaka, Japan. takayuki.yoshioka@shionogi.co.jp
authors.forename: T
authors.initials: T
authors.lastname: Yoshioka
authors.forename: T
authors.initials: T
authors.lastname: Wada
authors.forename: N
authors.initials: N
authors.lastname: Uchida
authors.forename: H
authors.initials: H
authors.lastname: Maki
authors.forename: H
authors.initials: H
authors.lastname: Yoshida
authors.forename: N
authors.initials: N
authors.lastname: Ide
authors.forename: H
authors.initials: H
authors.lastname: Kasai
authors.forename: K
authors.initials: K
authors.lastname: Hojo
authors.forename: K
authors.initials: K
authors.lastname: Shono
authors.forename: R
authors.initials: R
authors.lastname: Maekawa
authors.forename: S
authors.initials: S
authors.lastname: Yagi
authors.forename: R M
authors.initials: RM
authors.lastname: Hoffman
authors.forename: K
authors.initials: K
authors.lastname: Sugita
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D013437:Carbon-Sulfur Lyases / Q000008:administration & dosage / Q000494:pharmacology; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy / Q000401:mortality; D004357:Drug Synergism; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D008715:Methionine / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D016019:Survival Analysis; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D008715:Methionine; D013437:Carbon-Sulfur Lyases; C021558:L-methionine gamma-lyase; D005472:Fluorouracil